The effect of pentavalent antimonial compounds used in the treatment of cutaneous leishmaniasis on hemogram and biochemical parameters

Basit Öğe Kaydı
dc.contributor.authorAn, Isa
dc.contributor.authorHarman, Mehmet
dc.contributor.authorEsen, Mustafa
dc.contributor.authorCelik, Hakim
dc.date.accessioned2024-04-24T17:07:52Z
dc.date.available2024-04-24T17:07:52Z
dc.date.issued2019
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjective: The aim of this study was to analyze the effect of pentavalent antimonials used in the treatment of cutaneous leishmaniasis (CL) on hemogram and biochemical parameters. Material and methods: The study consisted of 168 patients diagnosed with CL after microscopic examination and treated with either systemic sodium stibogluconate (SSG) or meglumine antimonate (MA) 20 mg/kg/day for 14 days. The patients were divided into two groups as SSG and MA patients. Neutrophil count, leukocyte count, lymphocyte count, hemoglobin concentration, platelet count, amylase, lipase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen and serum creatinine levels were compared before and on the 14th day of the treatment. Results: There was a statistically significant decrease in the neutrophil, lymphocyte, leukocyte, platelet counts, and hemoglobin and blood urea nitrogen levels on the 14th day of the treatment when compared to the pre-treatment values. A statistically significant increase was found in the ALT, AST, amylase and lipase levels. No significant change was found in the serum creatinine levels. Conclusion: According to the results of our study, pentavalent antimonials given standard doses in the treatment of CL can lead to an increase in the pancreatic enzymes and transaminases and bone marrow suppression. We do not recommend any change in the treatment if these conditions are not corroborated by clinical findings.en_US
dc.identifier.doi10.1080/15569527.2019.1610887
dc.identifier.endpage297en_US
dc.identifier.issn1556-9527
dc.identifier.issn1556-9535
dc.identifier.issue3en_US
dc.identifier.pmid31039622
dc.identifier.scopus2-s2.0-85066054468
dc.identifier.scopusqualityQ3
dc.identifier.startpage294en_US
dc.identifier.urihttps://doi.org/10.1080/15569527.2019.1610887
dc.identifier.urihttps://hdl.handle.net/11468/17052
dc.identifier.volume38en_US
dc.identifier.wosWOS:000469732100001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofCutaneous and Ocular Toxicology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAmylaseen_US
dc.subjectAntimonyen_US
dc.subjectBiochemistryen_US
dc.subjectHemogramen_US
dc.subjectCutaneous Leishmaniasisen_US
dc.titleThe effect of pentavalent antimonial compounds used in the treatment of cutaneous leishmaniasis on hemogram and biochemical parametersen_US
dc.titleThe effect of pentavalent antimonial compounds used in the treatment of cutaneous leishmaniasis on hemogram and biochemical parameters
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu